Skip to main content

Jim Fraser to Speak at the FDLI’s 2022 Enforcement, Litigation and Compliance Conference

WASHINGTON, D.C. – Dec. 7, 2021 – James C. Fraser, a shareholder in the global law firm Greenberg Traurig, LLP’s Health Care & FDA Practice and Pharmaceutical, Medical Device and Health Care Practice, will participate in a panel discussion at the the Food and Drug Law Institute’s Enforcement, Litigation and Compliance Conference. The panel session, titled “Updates in Litigation Risks for FDA-Regulated Companies: Product Liability, Private Litigation, Consumer Class Actions, and More,” will take place virtually on Friday, December 10.

The Food & Drug Law Institute is a non-profit membership organization that offers education, training, publications, and professional engagement opportunities in the field of food and drug law and provides a venue for stakeholders to inform innovative public policy, law, and regulation.

Fraser’s panel will discuss crucial litigation trends, including state-based class actions, FDA enforcement, private litigation, and upcoming areas of risk, including post-pandemic litigation. Panelists include Brian Burgess, partner, Goodwin Procter; Donnelly McDowell, partner, Kelly Drye & Warren LLP; and moderator Anne K. Walsh, director, Hyman, Phelps & McNamara, PC. The panel will also explore ways to mitigate the risk of litigation and areas to watch for the future.

A former Associate Chief Counsel for Litigation with the U.S. Food and Drug Administration, Fraser joined the firm in September 2021 with deep experience defending pharmaceutical and medical device manufacturers in product liability litigation and defending FDA agency decisions surrounding pharmaceuticals, medical devices and other FDA-regulated products.

About Greenberg Traurig’s Pharmaceutical, Medical Device & Health Care Litigation Group: The Pharmaceutical, Medical Device & Health Care Litigation Group is an integral part of the firm’s 600+ attorney Litigation Practice. Founded by “trial wizard” Lori G. Cohen, this team is nationally recognized for its dynamic courtroom presence, responsiveness to clients, and deep subject matter knowledge. Recent recognitions include the shortlist for Benchmark Litigation’s 2020 “Product Liability Firm of the Year”; national rankings for 2019 “Product Liability & Mass Torts” from Chambers USA Guide; and national rankings for 2019 “Product Liability, Mass Tort and Class Action Defense: Pharmaceuticals and Medical Devices” from The Legal 500 United States.

About Greenberg Traurig’s Health Care & FDA Practice: Greenberg Traurig’s multidisciplinary Health Care & FDA Practice provides strategic counsel to a diverse group of companies and other organizations, helping them to respond proactively to the rapidly changing healthcare marketplace. The group combines dedicated experience in health care regulatory compliance and operational matters with the firm’s capabilities in corporate & securities, finance, tax, antitrust, ERISA, commercial and governmental litigation, restructuring, intellectual property and biotechnology, in order to provide a wide range of legal services.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has approximately 2,300 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 25 on the Am Law Global 100. The firm is net carbon neutral with respect to its office energy usage and Mansfield Rule 4.0 Plus Certified. Web: